How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mosapride-citrate-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Mosapride Citrate Tablets — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mosapride Citrate Tablets (Mosapride Citrate Tablets) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-HT4 receptor agonist. Area: Gastroenterology.

phase 3 5-HT4 receptor agonist 5-HT4 receptor Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Mosapride Citrate Tablets (Mosapride Citrate Tablets) — Xiyuan Hospital of China Academy of Chinese Medical Sciences. Mosapride citrate is a 5-HT4 receptor agonist that enhances gastric motility and accelerates gastric emptying.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Mosapride Citrate Tablets TARGET	Mosapride Citrate Tablets	Xiyuan Hospital of China Academy of Chinese Medical Sciences	phase 3	5-HT4 receptor agonist	5-HT4 receptor
S-268019-b	S-268019-b	Shionogi	phase 3	5-HT4 receptor partial agonist	5-HT4 receptor
DA-5219	DA-5219	Dong-A ST Co., Ltd.	phase 3	5-HT4 receptor partial agonist	5-HT4 receptor
OPN-375	OPN-375	Optinose US Inc.	phase 3	5-HT4 receptor agonist	5-HT4 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-HT4 receptor agonist class)

Optinose US Inc. · 1 drug in this class
Xiyuan Hospital of China Academy of Chinese Medical Sciences · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mosapride Citrate Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/mosapride-citrate-tablets. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing